Resultados de Búsqueda
It is not recommended the use of the tumor markers CA125 CA19-9 and CEA in the initial diagnosis of malignancy in unknown origin tumors.
Choosing Wisely ® : Things we do for no reason
JHM, Israilov S.
Research supports the use of the tumor markers CA125, CA19-9, and CEA as tests for monitoring, risk stratification, and treatment planning of ovarian, pancreatic, and colorectal tumors, respectively. Other clinicians have applied this paradigm with other biomarkers because of its feasible, noninvasive, and easy-to-use features. However, the study of biomarkers in symptomatic patients without a diagnosis does not add clarity to the differential diagnosis. Therefore, it is not recommended to ...
ver más ... 2021e
Choosing Wisely Australia
Canadian Society of Otolaryngology–Head & Neck Surgery
e
ver más ... 2021It is recommended to review the diagnostic process of cow's milk protein allergy in children with some symptoms.
Too Much Medicine - theBMJ [Demasiada Medicina-TheBMJ]
BMJ
Clinical practice guidelines designed to assist non-specialists in diagnosing cow's milk protein allergy in children may be unintentionally medicalizing normal children's symptoms and promoting overdiagnosis of cow's milk protein allergy. cow's milk. The study found that one in four parents reported two or more possible "mild to moderate" symptoms in their children each month. The proportion of affected children was higher at 3 months of age, when none of the children drank cow's milk, both in ...
ver más ... 2021The use of convalescent plasma is not recommended as a treatment for COVID-19 in patients with moderate to severe forms to reduce disease progression and the risk of death.
Evidencias COVID-19
Fundación Cardioinfantil
In patients hospitalized for COVID-19, the use of convalescent plasma as part of treatment is not associated with a reduction in mortality. Therefore, it is not considered a recommended therapy. Evidence quality: high (low risk of bias, accurate results, direct information on the clinical question). The impact of this intervention as prophylaxis in people at risk or as treatment in patients with mild or asymptomatic forms is not known. The effect of convalescent plasma for other important ...
ver más ... 2021Is not recommended the use of convalescent plasma as a treatment in patients hospitalized for COVID-19 to reduce the risk of disease progression or mortality.
Evidencias COVID-19
Fundación Cardioinfantil
In patients hospitalized for COVID-19, the use of convalescent plasma as part of treatment is not associated with a reduction in mortality. Therefore, it is not considered a recommended therapy. The impact of this intervention as prophylaxis in people at risk or as treatment in patients with mild or asymptomatic forms is unknown. The effect of convalescent plasma for other important clinical outcomes such as ICU admission, mechanical ventilation requirement, hospital stay, rates and time of ...
ver más ... 2021